leukocytoclastic

Breakthrough Therapy for Patients with Giant Cell Arteritis

FDA Grants Breakthrough Therapy Designation for GENENTECH’S Actemra® (tocilizumab) in Giant Cell Arteritis, A form of vasculitis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra® (tocilizumab) for giant…...

Read more

Support the VF through the Amazon Smile Program

Just in time for your holiday shopping! AmazonSmile is a simple and automatic way for you to support the Vasculitis Foundation every time you shop, at no cost to you.  When you shop at smile.amazon.com, you’ll find the exact same low prices, vast selection and convenient shopping experience as Amazon.com,…...

Read more

Brandon Qualifies for the 1500m Semi-Finals – Competes July 8th

Brandon Hudgins, elite runner, and vasculitis patient, continues his quest to make the 2016 U.S. Olympic Team!  On Thursday, July 7th, Brandon qualified for the semi-finals of the 1500m race with a time of 3:43.25 during the Olympic Team Trials in Eugene, Oregon.  The semi-finals will be held on Friday, July…...

Read more

KU Vasculitis Symposium – August 6 – Register Today

The Vasculitis Foundation is pleased to partner with the University of Kansas Medical Center to present the 2016 Vasculitis Symposium Educational Conference.  The one-day meeting will be held on Saturday, August 6 at the KU Edwards Campus in Overland Park, Kansas.  The conference will feature several vasculitis experts discussing treatment…...

Read more

VF Breaks $2,000,000 in Research Funding

In February, the VF Board of Directors approved three new research studies for funding, bringing to a total, $2,109,847,10, the VF has committed to supporting vasculitis research since 2002.  The VF Research Program, established in 2002, is funded through the generous donations of our members and extended vasculitis community.  The…...

Read more